Sangamo Therapeutics Q2 Adj EPS $(0.37) Misses $(0.34) Estimate, Sales $6.83M Miss $14.83M Estimate
Portfolio Pulse from saritha@benzinga.com
Sangamo Therapeutics reported Q2 losses of $0.37 per share, missing the analyst consensus estimate of $0.34 by 8.82%. This is a 27.59% decrease from the same period last year. The company also reported quarterly sales of $6.83 million, missing the analyst consensus estimate of $14.83 million by 53.91%. This is a 76.73% decrease from the same period last year.
August 08, 2023 | 8:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sangamo Therapeutics' Q2 results missed estimates, with a larger than expected loss per share and lower than expected sales.
Sangamo Therapeutics reported larger than expected losses and lower than expected sales for Q2. This negative financial performance is likely to negatively impact the company's stock price in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100